Pulmonary hypertension optimal screening in interstitial lung disease (PHOS-ILD): a scoring system for the detection of pulmonary hypertension in patients with interstitial lung disease.
Theodoros Karampitsakos, Evan Wasserman, Eleni Stagaki, Abhay Thottassery, Jorden Smith, Huda Asif, Brian Soto, Christian Arce Guzman, Jalen Hammonds, Anna Papasarantou, Agamemnon Bakakos, Ourania Papaioannou, Apostolos Matsioulas, Foteini Karakontaki, Konstantinos Loverdos, Eirini Kefalidou, Brenda M Juan-Guardela, Jose D Herazo-Maya, Adriano R Tonelli, Debabrata Bandyopadhyay
{"title":"Pulmonary hypertension optimal screening in interstitial lung disease (PHOS-ILD): a scoring system for the detection of pulmonary hypertension in patients with interstitial lung disease.","authors":"Theodoros Karampitsakos, Evan Wasserman, Eleni Stagaki, Abhay Thottassery, Jorden Smith, Huda Asif, Brian Soto, Christian Arce Guzman, Jalen Hammonds, Anna Papasarantou, Agamemnon Bakakos, Ourania Papaioannou, Apostolos Matsioulas, Foteini Karakontaki, Konstantinos Loverdos, Eirini Kefalidou, Brenda M Juan-Guardela, Jose D Herazo-Maya, Adriano R Tonelli, Debabrata Bandyopadhyay","doi":"10.3389/fmed.2026.1908302","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Pulmonary hypertension (PH) is a common comorbidity of interstitial lung disease (ILD). Timely detection may improve outcomes through implementation of PH specific treatments.</p><p><strong>Methods: </strong>Retrospective, multicenter study aiming to identify features that predict PH in patients with ILD. In the derivation cohort (ILD cohort-University of South Florida), we identified predictors of PH in ILD and created a scoring system using the rounded value of odds ratio for each significant parameter. Correlation with hemodynamic parameters was investigated in the derivation and validation cohort (Idiopathic Pulmonary Fibrosis cohort-Cleveland Clinic).</p><p><strong>Results: </strong>We included 164 patients with ILD that underwent right heart catheterization (RHC) [derivation cohort: <i>n</i> = 118, median age (years, 95% CI): 69.0 (65.9-71.0), female gender: 65 (54.6%), median mean pulmonary arterial pressure (mPAP) (mmHg, 95% CI): 25.0 (23.0-27.0), median pulmonary vascular resistance (PVR) [Wood units (WU), 95% CI]: 3.6 (3.0-4.3), validation cohort: <i>n</i> = 46, median age (95% CI): 63.0 (60.0-66.0), female gender: 17 (37%), median mPAP (mmHg, 95% CI): 20.5 (18.0-27.2), median PVR (WU, 95% CI): 3.1 (2.2-3.4)]. Parameters and optimal cut-offs that significantly predicted precapillary PH in the derivation cohort were: age>42 years, heart rate recovery (HRR) at 1 min ≤ 15 bpm in 6-min walk test (6 MWT), 6-min walk distance (6 MWD) ≤ 270 meters, B-type natriuretic peptide (BNP) > 136 pg/mL, pulmonary artery to ascending aorta diameter ratio (PA/AA) > 1 in high-resolution computed tomography (HRCT), main PA diameter > 29 mm in HRCT, right ventricular systolic pressure > 42 mmHg on echocardiogram. We created a PH detection model that ranged from 0 to 28. The optimal cut-off threshold for the detection of PH was > 14 (80% sensitivity, 68% specificity, AUC: 0.78). A simplified scoring system without BNP and main PA diameter (range: 0-21) maintained the same AUC. The simplified scoring system exhibited positive correlation with mean pulmonary artery pressure both in the derivation (rho = 0.47, <i>p</i> < 0.0001) and validation cohort (rho = 0.36, <i>p</i> = 0.013).</p><p><strong>Conclusion: </strong>This study demonstrates that incorporation of demographic, functional, imaging, and echocardiographic characteristics can optimize the early identification of precapillary PH in patients with ILD, paving the way to structured screening strategies. Timely detection of PH might lead to timely implementation of emerging PH specific treatments in patients with ILDs.</p>","PeriodicalId":12488,"journal":{"name":"Frontiers in Medicine","volume":"13 ","pages":"1908302"},"PeriodicalIF":3.6000,"publicationDate":"2026-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13678507/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3389/fmed.2026.1908302","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Pulmonary hypertension (PH) is a common comorbidity of interstitial lung disease (ILD). Timely detection may improve outcomes through implementation of PH specific treatments.
Methods: Retrospective, multicenter study aiming to identify features that predict PH in patients with ILD. In the derivation cohort (ILD cohort-University of South Florida), we identified predictors of PH in ILD and created a scoring system using the rounded value of odds ratio for each significant parameter. Correlation with hemodynamic parameters was investigated in the derivation and validation cohort (Idiopathic Pulmonary Fibrosis cohort-Cleveland Clinic).
Results: We included 164 patients with ILD that underwent right heart catheterization (RHC) [derivation cohort: n = 118, median age (years, 95% CI): 69.0 (65.9-71.0), female gender: 65 (54.6%), median mean pulmonary arterial pressure (mPAP) (mmHg, 95% CI): 25.0 (23.0-27.0), median pulmonary vascular resistance (PVR) [Wood units (WU), 95% CI]: 3.6 (3.0-4.3), validation cohort: n = 46, median age (95% CI): 63.0 (60.0-66.0), female gender: 17 (37%), median mPAP (mmHg, 95% CI): 20.5 (18.0-27.2), median PVR (WU, 95% CI): 3.1 (2.2-3.4)]. Parameters and optimal cut-offs that significantly predicted precapillary PH in the derivation cohort were: age>42 years, heart rate recovery (HRR) at 1 min ≤ 15 bpm in 6-min walk test (6 MWT), 6-min walk distance (6 MWD) ≤ 270 meters, B-type natriuretic peptide (BNP) > 136 pg/mL, pulmonary artery to ascending aorta diameter ratio (PA/AA) > 1 in high-resolution computed tomography (HRCT), main PA diameter > 29 mm in HRCT, right ventricular systolic pressure > 42 mmHg on echocardiogram. We created a PH detection model that ranged from 0 to 28. The optimal cut-off threshold for the detection of PH was > 14 (80% sensitivity, 68% specificity, AUC: 0.78). A simplified scoring system without BNP and main PA diameter (range: 0-21) maintained the same AUC. The simplified scoring system exhibited positive correlation with mean pulmonary artery pressure both in the derivation (rho = 0.47, p < 0.0001) and validation cohort (rho = 0.36, p = 0.013).
Conclusion: This study demonstrates that incorporation of demographic, functional, imaging, and echocardiographic characteristics can optimize the early identification of precapillary PH in patients with ILD, paving the way to structured screening strategies. Timely detection of PH might lead to timely implementation of emerging PH specific treatments in patients with ILDs.
期刊介绍:
Frontiers in Medicine publishes rigorously peer-reviewed research linking basic research to clinical practice and patient care, as well as translating scientific advances into new therapies and diagnostic tools. Led by an outstanding Editorial Board of international experts, this multidisciplinary open-access journal is at the forefront of disseminating and communicating scientific knowledge and impactful discoveries to researchers, academics, clinicians and the public worldwide.
In addition to papers that provide a link between basic research and clinical practice, a particular emphasis is given to studies that are directly relevant to patient care. In this spirit, the journal publishes the latest research results and medical knowledge that facilitate the translation of scientific advances into new therapies or diagnostic tools. The full listing of the Specialty Sections represented by Frontiers in Medicine is as listed below. As well as the established medical disciplines, Frontiers in Medicine is launching new sections that together will facilitate
- the use of patient-reported outcomes under real world conditions
- the exploitation of big data and the use of novel information and communication tools in the assessment of new medicines
- the scientific bases for guidelines and decisions from regulatory authorities
- access to medicinal products and medical devices worldwide
- addressing the grand health challenges around the world